4//SEC Filing
Hoffman Steve 4
Accession 0000899243-22-031354
CIK 0001537917other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:01 PM ET
Size
7.5 KB
Accession
0000899243-22-031354
Insider Transaction Report
Form 4
Hoffman Steve
DirectorCEO and Chief Science Officer10% Owner
Transactions
- Disposition to Issuer
Common Stock
2022-09-16−20,022,566→ 0 total - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−88,000→ 0 totalExercise: $0.31Exp: 2032-08-23→ Common Stock (88,000 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 877,388 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
- [F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.
Documents
Issuer
TYME TECHNOLOGIES, INC.
CIK 0001537917
Entity typeother
Related Parties
1- filerCIK 0001711342
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 6:01 PM ET
- Size
- 7.5 KB